Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Hiroyuki Hanzawa"'
Autor:
Ryohei Katayama, Bo Gong, Noriko Togashi, Masaya Miyamoto, Masaki Kiga, Shiho Iwasaki, Yasuki Kamai, Yuichi Tominaga, Yasuyuki Takeda, Yoshiko Kagoshima, Yuki Shimizu, Yosuke Seto, Tomoko Oh-hara, Sumie Koike, Naoki Nakao, Hiroyuki Hanzawa, Kengo Watanabe, Satoshi Yoda, Noriko Yanagitani, Aaron N. Hata, Alice T. Shaw, Makoto Nishio, Naoya Fujita, Takeshi Isoyama
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
The treatment of ROS1-rearranged non-small cell lung cancer with the TKI crizotinib is limited due to the emergence of resistance. Here, the authors develop a new ROS1/NTRK inhibitor, DS-6051b, which overcomes crizotinib resistance in preclinical mod
Externí odkaz:
https://doaj.org/article/1fb146a2c258459e81f631757ffb5a98
Autor:
Shin-Ichiro Miura, Naoki Nakao, Hiroyuki Hanzawa, Yoshino Matsuo, Keijiro Saku, Sadashiva S Karnik
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e79914 (2013)
While the molecular structures of angiotensin II (Ang II) type 1 (AT1) receptor blockers (ARBs) are very similar, they are also slightly different. Although each ARB has been shown to exhibit a unique mode of binding to AT1 receptor, different positi
Externí odkaz:
https://doaj.org/article/9f56b096fbab474a910b142062c1772b
Autor:
Shin-ichiro Miura, Yoshihiro Kiya, Hiroyuki Hanzawa, Naoki Nakao, Masahiro Fujino, Satoshi Imaizumi, Yoshino Matsuo, Hiroaki Yanagisawa, Hiroyuki Koike, Issei Komuro, Sadashiva S. Karnik, Keijiro Saku
Publikováno v:
PLoS ONE, Vol 8, Iss 5 (2013)
Externí odkaz:
https://doaj.org/article/ea200013e5684663a7ca34a88b61d55a
Autor:
Shin-ichiro Miura, Yoshihiro Kiya, Hiroyuki Hanzawa, Naoki Nakao, Masahiro Fujino, Satoshi Imaizumi, Yoshino Matsuo, Hiroaki Yanagisawa, Hiroyuki Koike, Issei Komuro, Sadashiva S Karnik, Keijiro Saku
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e37974 (2012)
Small differences in the chemical structures of ligands can be responsible for agonism, neutral antagonism or inverse agonism toward a G-protein-coupled receptor (GPCR). Although each ligand may stabilize the receptor conformation in a different way,
Externí odkaz:
https://doaj.org/article/e67898d977f84a6f9749664b86ef1e48
Autor:
Reimar Abraham, Johannes Bange, Toshinori Agatsuma, Roger W. Chapman, Dieter Häussinger, Masaharu Hanai, Alberto Martinez, Emi Imai, Hiroyuki Hanzawa, Mizuki Takahashi, Shuntaro Saito, Mauricio Redondo-Müller, Jan-Peter A. Mayer, Peter Wirtz, Yoshinori Kashimoto, Hironobu Komori, Reimi Kawaida, Yoko Oda, Shinko Hayashi, Ichiro Watanabe, Katrin Gruner, Tanja Lange, Toshiaki Ohtsuka, Keisuke Fukuchi, René Bartz
The FGFR4/FGF19 signaling axis is overactivated in 20% of liver tumors and currently represents a promising targetable signaling mechanism in this cancer type. However, blocking FGFR4 or FGF19 has proven challenging due to its physiological role in s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3557d25f822e42d592793065c67874d0
https://doi.org/10.1158/1535-7163.c.6539353
https://doi.org/10.1158/1535-7163.c.6539353
Autor:
Sai-Hong Ignatius Ou, Pasi A. Jänne, Takashi Seto, Yanfei Gao, Qinying Zhao, Frank Fan, Meijing Li, Chenhui Deng, Kenji Nakamaru, Takeshi Isoyama, Masaya Tachibana, Hiroyuki Hanzawa, Naoki Nakao, Giorgio Senaldi, Alexa B. Schrock, Russell Madison, Heather A. Wakelee, Thomas Yang Sun, Viola W. Zhu, Yuki Shimizu, Ryohei Katayama, Alice T. Shaw, Erkut Borazanci, Kyriakos P. Papadopoulos
Purpose:Taletrectinib (DS-6051b/AB-106) is an oral, tyrosine kinase inhibitor of ROS1 and NTRK with potent preclinical activity against ROS1 G2032R solvent-front mutation among others. We report the first-in-human U.S. phase I results of taletrectini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c0fc1994ca625c18ce962fd334f7b3a
https://doi.org/10.1158/1078-0432.c.6529236.v1
https://doi.org/10.1158/1078-0432.c.6529236.v1
Autor:
Sai-Hong Ignatius Ou, Pasi A. Jänne, Takashi Seto, Yanfei Gao, Qinying Zhao, Frank Fan, Meijing Li, Chenhui Deng, Kenji Nakamaru, Takeshi Isoyama, Masaya Tachibana, Hiroyuki Hanzawa, Naoki Nakao, Giorgio Senaldi, Alexa B. Schrock, Russell Madison, Heather A. Wakelee, Thomas Yang Sun, Viola W. Zhu, Yuki Shimizu, Ryohei Katayama, Alice T. Shaw, Erkut Borazanci, Kyriakos P. Papadopoulos
Supplemental tables and figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47373f841d777bd84e2a008fd2ff0bf3
https://doi.org/10.1158/1078-0432.22475964.v1
https://doi.org/10.1158/1078-0432.22475964.v1
Autor:
Takaaki Akasaka, Ryoichi Hamasuna, Hisami Aono, Masahiro Matsumoto, Jørgen Skov Jensen, Ikko Tomisaki, Hiroyuki Hanzawa, Ayako Moritomo, Naohiro Fujimoto
Publikováno v:
Journal of Infection and Chemotherapy. 28:377-383
Introduction The mechanisms of fluoroquinolone-resistance of Mycoplasma genitalium were analysed by a new method. Methods M. genitalium strains from urinary sediments of patients with urethritis were isolated and examined antimicrobial susceptibiliti
Autor:
Daisuke Kozai, Nobutaka Numoto, Kouki Nishikawa, Akiko Kamegawa, Shohei Kawasaki, Yoko Hiroaki, Katsumasa Irie, Atsunori Oshima, Hiroyuki Hanzawa, Kousei Shimada, Yutaka Kitano, Yoshinori Fujiyoshi
Publikováno v:
Journal of Molecular Biology. 435:168049
Autor:
Miwa Fujisaki, Yuji Tokunaga, Ichio Shimada, Hajime Kamoshida, Hiroyuki Hanzawa, Takeshi Takizawa, Koh Takeuchi, Imai Misaki
Publikováno v:
Angewandte Chemie International Edition. 60:6567-6572
Cyclorasins 9A5 and 9A54 are 11-mer cyclic peptides that inhibit the Ras-Raf protein interaction. The peptides share a cell-penetrating peptide (CPP)-like motif; however, only cyclorasin 9A5 can permeabilize cells to exhibit strong cell-based activit